vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $48.4M, roughly 1.2× First Foundation Inc.). First Foundation Inc. runs the higher net margin — -97.9% vs -246.8%, a 148.9% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 7.6%). Vanda Pharmaceuticals Inc. produced more free cash flow last quarter ($-29.5M vs $-35.2M). Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs -2.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
FFWM vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $57.2M |
| Net Profit | $-8.0M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | -97.5% | -70.5% |
| Net Margin | -97.9% | -246.8% |
| Revenue YoY | 421.7% | 7.6% |
| Net Profit YoY | 43.0% | -2774.3% |
| EPS (diluted) | $-0.09 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $57.2M | ||
| Q3 25 | $63.6M | $56.3M | ||
| Q2 25 | $51.4M | $52.6M | ||
| Q1 25 | $71.4M | $50.0M | ||
| Q4 24 | $9.3M | $53.2M | ||
| Q3 24 | $9.2M | $47.7M | ||
| Q2 24 | $57.5M | $50.5M | ||
| Q1 24 | $51.1M | $47.5M |
| Q4 25 | $-8.0M | $-141.2M | ||
| Q3 25 | $-146.3M | $-22.6M | ||
| Q2 25 | $-7.7M | $-27.2M | ||
| Q1 25 | $6.9M | $-29.5M | ||
| Q4 24 | $-14.1M | $-4.9M | ||
| Q3 24 | $-82.2M | $-5.3M | ||
| Q2 24 | $3.1M | $-4.5M | ||
| Q1 24 | $793.0K | $-4.1M |
| Q4 25 | -97.5% | -70.5% | ||
| Q3 25 | -92.7% | -55.6% | ||
| Q2 25 | -21.1% | -73.2% | ||
| Q1 25 | 8.8% | -82.0% | ||
| Q4 24 | -247.7% | -19.3% | ||
| Q3 24 | -1276.7% | -23.1% | ||
| Q2 24 | 4.6% | -20.1% | ||
| Q1 24 | -0.2% | -19.5% |
| Q4 25 | -97.9% | -246.8% | ||
| Q3 25 | -230.1% | -40.1% | ||
| Q2 25 | -15.0% | -51.7% | ||
| Q1 25 | 9.7% | -58.9% | ||
| Q4 24 | -152.2% | -9.2% | ||
| Q3 24 | -896.9% | -11.2% | ||
| Q2 24 | 5.4% | -9.0% | ||
| Q1 24 | 1.6% | -8.7% |
| Q4 25 | $-0.09 | $-2.40 | ||
| Q3 25 | $-1.78 | $-0.38 | ||
| Q2 25 | $-0.09 | $-0.46 | ||
| Q1 25 | $0.08 | $-0.50 | ||
| Q4 24 | $-0.24 | $-0.09 | ||
| Q3 24 | $-1.23 | $-0.09 | ||
| Q2 24 | $0.05 | $-0.08 | ||
| Q1 24 | $0.01 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $912.6M | $327.2M |
| Total Assets | $11.9B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $84.9M | ||
| Q3 25 | $1.7B | $70.0M | ||
| Q2 25 | $1.1B | $81.0M | ||
| Q1 25 | $1.0B | $111.8M | ||
| Q4 24 | $1.0B | $102.3M | ||
| Q3 24 | $1.1B | $100.5M | ||
| Q2 24 | $1.4B | $103.0M | ||
| Q1 24 | $1.6B | $125.2M |
| Q4 25 | $912.6M | $327.2M | ||
| Q3 25 | $917.9M | $466.0M | ||
| Q2 25 | $1.1B | $486.3M | ||
| Q1 25 | $1.1B | $511.4M | ||
| Q4 24 | $1.1B | $538.5M | ||
| Q3 24 | $1.1B | $541.2M | ||
| Q2 24 | $933.2M | $542.5M | ||
| Q1 24 | $928.7M | $544.0M |
| Q4 25 | $11.9B | $488.9M | ||
| Q3 25 | $11.9B | $601.1M | ||
| Q2 25 | $11.6B | $624.7M | ||
| Q1 25 | $12.6B | $631.9M | ||
| Q4 24 | $12.6B | $656.2M | ||
| Q3 24 | $13.4B | $645.1M | ||
| Q2 24 | $13.7B | $651.4M | ||
| Q1 24 | $13.6B | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $-29.4M |
| Free Cash FlowOCF − Capex | $-35.2M | $-29.5M |
| FCF MarginFCF / Revenue | -72.8% | -51.6% |
| Capex IntensityCapex / Revenue | 6.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $-29.4M | ||
| Q3 25 | $9.2M | $-31.6M | ||
| Q2 25 | $-16.3M | $-15.3M | ||
| Q1 25 | $-552.0K | $-33.1M | ||
| Q4 24 | $-8.7M | $-1.8M | ||
| Q3 24 | $14.2M | $-14.6M | ||
| Q2 24 | $-9.1M | $-6.9M | ||
| Q1 24 | $7.2M | $7.6M |
| Q4 25 | $-35.2M | $-29.5M | ||
| Q3 25 | $8.6M | $-31.8M | ||
| Q2 25 | $-16.7M | $-15.6M | ||
| Q1 25 | $-2.5M | $-33.6M | ||
| Q4 24 | $-11.4M | $-2.0M | ||
| Q3 24 | $13.4M | $-14.7M | ||
| Q2 24 | $-9.4M | $-7.0M | ||
| Q1 24 | $5.9M | $7.6M |
| Q4 25 | -72.8% | -51.6% | ||
| Q3 25 | 13.5% | -56.5% | ||
| Q2 25 | -32.4% | -29.6% | ||
| Q1 25 | -3.5% | -67.1% | ||
| Q4 24 | -123.5% | -3.8% | ||
| Q3 24 | 146.2% | -30.9% | ||
| Q2 24 | -16.3% | -13.9% | ||
| Q1 24 | 11.6% | 15.9% |
| Q4 25 | 6.9% | 0.2% | ||
| Q3 25 | 1.0% | 0.3% | ||
| Q2 25 | 0.8% | 0.6% | ||
| Q1 25 | 2.8% | 0.9% | ||
| Q4 24 | 29.4% | 0.4% | ||
| Q3 24 | 9.0% | 0.3% | ||
| Q2 24 | 0.4% | 0.2% | ||
| Q1 24 | 2.5% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFWM
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
